Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colon cancer screening
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colon cancer screening or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colon cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. The effect on mortality of screening for lung cancer with modern chest radiographs is unknown.To evaluate the effect on mortality of screening for lung cancer using radiographs in the Prostate, Lung, Colorectal, and Ovarian (PLCO) CancerScreening Trial.Randomized controlled trial that involved 154,901 participants aged 55 through 74 years, 77,445 of whom were assigned (...) % at years 1 through 3; the rate of screening use in the usual care group was 11%. Cumulative lung cancer incidence rates through 13 years of follow-up were 20.1 per 10,000 person-years in the intervention group and 19.2 per 10,000 person-years in the usual care group (rate ratio [RR]; 1.05, 95% CI, 0.98-1.12). A total of 1213 lung cancer deaths were observed in the intervention group compared with 1230 in usual care group through 13 years (mortality RR, 0.99; 95% CI, 0.87-1.22). Stage and histology were
summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of a programme to screen the population for colorectalcancer, using colonoscopy, flexible sigmoidoscopy, second-generation colon capsule endoscopy (CCE), the faecal immunochemical test (FIT), or the guaiac faecal occult blood test (FOBT). FIT every year was the most cost-effective (...) strategy, in France, but further studies were needed. The cost-effectiveness methods were robust and key areas of uncertainty were investigated. The authors’ conclusions appear to be valid. Type of economic evaluation Cost-effectiveness analysis Study objective The objective was to examine the cost-effectiveness of a programme to screen the population for colorectalcancer, using colonoscopy, flexible sigmoidoscopy, second-generation colon capsule endoscopy (CCE), the faecal immunochemical test (FIT
Effect of evidence based risk information on "informed choice" in colorectalcancerscreening: randomised controlled trial. To compare the effect of evidence based information on risk with that of standard information on informed choice in screening for colorectal cancer.Randomised controlled trial with 6 months' follow-up.German statutory health insurance scheme.1577 insured people who were members of the target group for colorectalcancerscreening (age 50-75, no history of colorectalcancer (...) ).Brochure with evidence based risk information on colorectalcancerscreening and two optional interactive internet modules on risk and diagnostic tests; official information leaflet of the German colorectalcancerscreening programme (control).The primary end point was "informed choice," comprising "knowledge," "attitude," and "combination of actual and planned uptake." Secondary outcomes were "knowledge" and "combination of actual and planned uptake." Knowledge and attitude were assessed after 6 weeks
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) CancerScreening Randomized Controlled Trial. Screening for ovarian cancer with cancer antigen 125 (CA-125) and transvaginal ultrasound has an unknown effect on mortality.To evaluate the effect of screening for ovarian cancer on mortality in the Prostate, Lung, Colorectal and Ovarian (PLCO) CancerScreening Trial.Randomized controlled trial of 78,216 women aged 55 to 74 years assigned to undergo (...) %). There were 2924 deaths due to other causes (excluding ovarian, colorectal, and lung cancer) (76.6 per 10,000 person-years) in the intervention group and 2914 deaths (76.2 per 10,000 person-years) in the usual care group (RR, 1.01; 95% CI, 0.96-1.06).Among women in the general US population, simultaneous screening with CA-125 and transvaginal ultrasound compared with usual care did not reduce ovarian cancer mortality. Diagnostic evaluation following a false-positive screening test result was associated
Effect of repeated invitations on uptake of colorectalcancerscreening using faecal occult blood testing: analysis of prevalence and incidence screening. To analyse the effects of prevalence and incidence screening on uptake and detection of cancer in an ongoing, dynamic programme for colorectalscreening using faecal occult blood testing.Analysis of prevalence and incidence screening.Three rounds of biennial colorectalscreening using the guaiac faecal occult blood test in east and north east (...) % and for a second incidence screen were 1.1% and 94.5%. The positive predictive value of a positive faecal occult blood test result for cancer was 11.0% for prevalence screening, 6.5% for the first incidence screen, and 7.5% for the second incidence screen. The corresponding values for the positive predictive value for adenoma were 35.5%, 29.4%, and 26.7%. The proportion of cancers at stage I dropped from 46.5% for prevalence screening to 41% for first incidence screening and 35% for second incidence
Analysis of deaths occurring within the Nottingham trial of faecal occult blood screening for colorectalcancer To report the causes of, and ages at, death of subjects in an English colorectalcancerscreening trial.Analysis of 78 708 deaths occurring between 1981 and 2008, within the Nottingham randomised controlled trial of biennial faecal occult blood testing.Cause of death, age at death by sex and by cause.Significantly more subjects died from verified colorectalcancer in the trial's (...) control group than in the intervention group (3.2% vs 2.9%). For no other major cause of death was the difference in proportion across the two groups statistically significant. Age at death was lower for cancer than for other principal causes, except for ischaemic heart disease among women. However, mean age at death was higher for colorectalcancer than for other cancers, except for prostate cancer among men. Increasing levels of material deprivation significantly lowered the expected ages at death
Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectalcancerscreening Although some studies have shown that the quantitative, immunochemical fecal occult blood test (FOBT) (qFIT) has better performance characteristics than the standard guaiac-based FOBT (GT) for identifying advanced colorectalneoplasia (ACRN), there is limited information on test performance of these tests in average-risk populations.Seven (...) hundred seventy consecutive average-risk patients from four centers who were undergoing screening colonoscopy also provided stool samples. Stool specimens from three consecutive bowel movements were applied to a hemoccult II test card (Beckman Coulter, Fullerton, CA) and OC-SENSA MICRO (Eiken Chemical, Tokyo, Japan) sampling probes at the same time. We measured the diagnostic value of the qFIT for detecting an ACRN by using three criteria: sensitivity, specificity, and likelihood ratios. A receiver
at a cost of $350 per test if the relative adherence to stool DNA testing were at least 50% better than that with other screening tests.None of the results changed substantially when a cohort of persons aged 50 years was considered.No pathways other than the traditional adenoma-carcinoma sequence were modeled.Stool DNA testing could be a cost-effective alternative for colorectalcancerscreening if the cost of the test substantially decreased or if its availability would entice a large fraction (...) Stool DNA testing to screen for colorectalcancer in the medicare population: a cost-effectiveness analysis. The Centers for Medicare & Medicaid Services considered whether to reimburse stool DNA testing for colorectalcancerscreening among Medicare enrollees.To evaluate the conditions under which stool DNA testing could be cost-effective compared with the colorectalcancerscreening tests currently reimbursed by the Centers for Medicare & Medicaid Services.Comparative microsimulation modeling
A randomized controlled trial of a multilevel intervention to increase colorectalcancerscreening among Latino immigrants in a primary care facility Latino immigrants face a higher burden of colorectalcancer (CRC) and screening rates are low.To assess the effectiveness of a multilevel intervention in increasing the rate of CRC screening among Latino immigrants.A randomized controlled trial, with randomization at the physician level.Pairs of 65 primary care physicians and 65 Latino immigrant (...) patients participated, 31 in the intervention and 34 in the control group.CRC educational video in Spanish on a portable personal digital video display device accompanied by a brochure with key information for the patient, and a patient-delivered paper-based reminder for their physician.Completed CRC screening, physician recommendation for CRC screening, and patient adherence to physician recommended CRC screening.The overall rate of completed screening for CRC was 55% for the intervention and 18
How equitable are colorectalcancerscreening programs which include FOBTs? A review of qualitative and quantitative studies To review published literature on the equity of participation in colorectalcancerscreening amongst different population subgroups, in addition to identifying factors identified as barriers and facilitators to equitable screening. Studies were included in the review if they included FOBT as at least one of the screening tests.Relevant published articles were identified (...) through systematic electronic searches of selected databases and the examination of the bibliographies of retrieved articles. Studies of the association with colorectalcancerscreening test participation, barriers to equitable participation in screening, and studies examining interventional actions to facilitate screening test participation were included. Data extraction and analysis was undertaken using an approach to the synthesis of qualitative and quantitative studies called Realist Review.Sixty
Could the colonic capsule PillCam Colon be clinically useful for selecting patients who deserve a complete colonoscopy?: results of clinical comparison with colonoscopy in the perspective of colorectalcancerscreening Preliminary studies have shown the possibility of detecting colonic polyps and tumors using the PillCam Colon capsule endoscope (CCE) (Given Imaging, Yoqneam, Israel). The aim of this study was to evaluate the ability of CCE to detect clinically relevant colonic findings (...) as compared with colonoscopy, and further, to test the assumption that CCE used in the frame of colorectalcancer (CRC) screening could accurately discriminate patients deserving a complete colonoscopy.A total of 128 patients (67 men, 55+/-14 years) with an indication of colonoscopy were investigated by CCE, followed by colonoscopy under general anesthesia on the next day. Bowel cleansing was carried out according to a previously published protocol (3 l polyethylene glycol+2 doses of sodium phosphate
Screening for colorectalcancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy Screening for colorectalcancer (CRC) is widely accepted, but there is no consensus on the preferred strategy. We conducted a randomised trial comparing participation and detection rates (DR) per screenee of guaiac-based faecal occult blood test (gFOBT), immunochemical FOBT (FIT), and flexible sigmoidoscopy (FS) for CRC screening.A representative (...) %) for gFOBT, 61.5% (CI, 60.1 to 62.9%) for FIT and 32.4% (CI, 31.1 to 33.7%) for FS screening. gFOBT was positive in 2.8%, FIT in 4.8% and FS in 10.2%. The DR of advanced neoplasia was significantly higher in the FIT (2.4%; OR, 2.0; CI, 1.3 to 3.1) and the FS arm (8.0%; OR, 7.0; CI, 4.6 to 10.7) than the gFOBT arm (1.1%). FS demonstrated a higher diagnostic yield of advanced neoplasia per 100 invitees (2.4; CI, 2.0 to 2.8) than gFOBT (0.6; CI, 0.4 to 0.8) or FIT (1.5; CI, 1.2 to 1.9) screening.This
is needed and must be a scientific priority. Screening is defined as the testing of individuals for a disease prior to the onset of any symptoms. The goal of colorectalcancerscreening is to reduce disease-specific mortality through prevention and early detection. Colorectalcancerscreening, as with any screening test, is most effective when it is applied to a large percentage of eligible people and utilized appropriately. Major published guidelines describe the eligible target population (...) people are newly diagnosed with colorectalcancer and 50,000 die. Polyps are abnormal growths of tissue along the lining of the colon. Many polyps are harmless, but a common type of polyp, the adenoma, can develop over time into a colorectalcancer. An effective way to reduce mortality from colorectalcancer is to screen for it and its precursor, the adenoma. Although screening methods have been available for decades and new methods continue to develop, screening rates remain low. The purpose
A decision aid to support informed choices about bowelcancerscreening among adults with low education: randomised controlled trial. To determine whether a decision aid designed for adults with low education and literacy can support informed choice and involvement in decisions about screening for bowel cancer.Randomised controlled trial.Areas in New South Wales, Australia identified as socioeconomically disadvantaged (low education attainment, high unemployment, and unskilled occupations).572 (...) adults aged between 55 and 64 with low educational attainment, eligible for bowelcancer screening.Patient decision aid comprising a paper based interactive booklet (with and without a question prompt list) and a DVD, presenting quantitative risk information on the possible outcomes of screening using faecal occult blood testing compared with no testing. The control group received standard information developed for the Australian national bowelscreening programme. All materials and a faecal occult
published sources. Measure of benefit: Quality-adjusted life-years (QALYs) were the summary benefit measure and they were discounted at an annual rate of 5%. Cost data: The economic analysis included the direct medical costs of the colorectalcancerscreening tests, the treatment of screening-related complications, and the treatment of colorectalcancer, which depended on the disease stage. The unit costs were reported for the screening tests; the other costs were presented as category totals. The costs (...) , and it is not possible to judge their validity. Some data were varied in the sensitivity analysis. QALYs were a valid measure, as colorectalcancer has an impact on survival and quality of life. They can also be compared with the benefits for disease interventions. Costs: The economic analysis was consistent with the perspective adopted. The authors stated that the costs of developing a screening programme were not considered because the analysis focused on the screening tests per patient pathway. The unit costs
Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectalneoplasms: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.